clinical trial · NCT06934226
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development, LLC·phase3·active not recruiting·n = 752
Plaque PsoriasisJNJ-77242113Matching Placebo to JNJ-77242113UstekinumabMatching Placebo to Ustekinumab
brief summary
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
started
Apr 15, 2025
primary completion
Nov 17, 2025
completion
Aug 20, 2027
last updated
Jul 6, 2026
official title
77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol